Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Pulmonary hypertension or elevation of the pressure in the pulmonary vessels, results from
various clinical conditions. It may be idiopathic (of unknown cause) or associated with
numerous diseases including cardiovascular and lung disorders. Affected individuals suffer
from progressive shortness of breath and, in its most sever forms; pulmonary hypertension
carries a worse prognosis than many types of cancer. There is no test currently that can
easily and non-invasively detect abnormalities of the pulmonary circulation. Presently there
is no cure for pulmonary hypertension and substantial research efforts are dedicated to the
development of new drugs that will stop progression or better yet, reverse the disease
process. The investigators do not know if any of the drugs currently commercialized for
pulmonary hypertension directly improve the status of the pulmonary vessels since no test
currently provides this information. Direct earlier detection of lung vessel abnormalities
associated with pulmonary hypertension using a sensitive and non-invasive test would allow
not only earlier testing of these and of new drugs, but would provide a much better surrogate
of disease severity allowing more efficient pre-clinical drug testing. The aim of this phase
II study is to evaluate the safety of PulmoBind in participants with pulmonary hypertension
and its potential to detect abnormal pulmonary circulation associated within pulmonary
hypertension.